Thankful to ASMB and The University of Manchester for hosting this basement membrane workshop and allowing me to share my work. Received great feedback and learned a ton from the other attendees. Here is a nice video highlight. youtu.be/Fu5AkQ9JoRE?si…

Wondering about role of basement membrane, extracellular matrix, and ECM receptors in cancer? Check out our review published in Matrix Biology! ASMB #ecmatrix Vanderbilt Health @VUMCHemOnc @VUMC_Cancer Vanderbilt University Medical Center @VUMCResearch @VUMC_Medicine pubmed.ncbi.nlm.nih.gov/38677444/

Congrats Daenielle Lang and Eric Lander, MD on graduating from the @VUMCHemOnc fellowship! Exceptional doctors. Working with you in clinic is one of my favorite parts of the job! @VUMC_Medicine @VUMC_Cancer Kristin Ancell Vivek Patel, MD

Lizzy (my favorite golfer) and I had a great time watching Tillie Claggett and Vanderbilt Women's Golf at the Mason Rudolph Championship at the Vanderbilt Legends Club course! Vanderbilt University Vanderbilt Athletics

Dr. W. Kimryn Rathmell will step down as Dr. Kimryn Rathmell, effective Monday, January 20. Read Dr. Rathmell’s thoughts in her announcement below.

Thanks to everyone who contacted Congress to advocate for kidney cancer patients and research, including KidneyCAN. We will have less funding this year, but we will continue to provide great care for patients. Hoping funding is restored next year.

Trying to keep up with all the recent @kidneycancer biomarker developments? Check out our new review for all the latest updates. Brian Rini, MD Vanderbilt University Medical Center pubmed.ncbi.nlm.nih.gov/40240621/

Ask Congress to fully restore federal funding for kidney cancer research. Our patients suffer from this disease every day. The status quo is not ok. Click the link below to email your Senators and Representative. It takes 1 minute. KidneyCAN takeaction.io/rallyfoundatio…

Impressive and remarkable biomarker-driven 1L by Scott Haake, MD, PhD in OPTIC RCC, Ph.II trial: RNAseq-guided nivolumab+cabozantinib for angiogenic cluster 1/2. ORR 71% (PR 71%, SD 29%, PD 0); 100% tumor shrinkage (n=21). Prospectively selected tissue-based rna biomarker to guide

Scott Haake, MD, PhD showing initial findings from OPTIC RCC study showing biopsy driven biomarker studies are feasible in mccRCC. As anticipated in angiogenic driven tumors IO/TKI with phenomenal response rates with no progressive disease. Congrats to study team Brian Rini, MD #ESMO25

Dear Colleagues at #ESMO25 An Honor to introduce our Faculty 🚨 Brian Rini, MD Discussing the OPTIC Trial in #KidneyCancer 2591O - Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel

In #OPTICRCC, metastatic #ccRCC patients with cluster 1/2 (#angiogenic) tumors tx w/ cabo/nivo showed 71% ORR (&100% tumor reduction rate), an increase relative to unselected historical controls. Important trial evaluating #biology & #VEGF dependence of ccRCC #ESMO25

Outstanding presentation by Scott Haake, MD, PhD on this pragmatic and first biomarker-driven trial in mccRCC! Another fine example of using biomarker analyses from a negative Ph3 trial to inform future hypothesis-driven, biomarker-guided trials. Looking forward to extended follow up

💡 OPTIC RCC: precision oncology in action! Using RNA-seq cluster biology to enrich for response in frontline #RCC. 🔹 76% ORR in angiogenic clusters with nivo+cabo 🔹 Ipi+nivo enrolling immune clusters next Next steps ➡️ expand IO arm & move toward liquid biopsy to replace

RNA Sequencing Signatures May Guide Treatment Selection in Advanced ccRCC Scott Haake, MD, PhD Vanderbilt School of Medicine ESMO - Eur. Oncology #ESMO25 #medtwitter #oncology onclive.com/view/rna-seque…

Scott Haake, MD, PhD concludes: The Phase II trial met its primary endpoint! Using tumor RNA sequencing, Cabozantinib + Nivolumab showed 100% tumor shrinkage. A win for biomarker-driven precision oncology! #ESMO25 #Oncology #PrecisionMedicine #ClinicalTrial #Cabozantinib #Nivolumab

Had a great time at #ESMO25 in Berlin. In OPTIC RCC trial, IDing angiogenic tumors via novel RNAseq biomarker enriches for response to cabo/nivo in ccRCC. Thx to Amanda Nizam, MD for the chat! Brian Rini, MD Vanderbilt Health guoncologynow.com/post/optic-rcc…